The FDA has approved a combination of Pfizer’s Braftovi and Merck KGaA’s Erbitux for a form of untreated metastatic colorectal cancer, the first targeted drug regimen for this form of the disease.

SM Prime said that SMXCITE, together with SMX Manila, will offer over 35,000 square meters of combined space, further reinforcing the MOA Complex’s appeal as a destination for international ...

Two-drug therapy with Braftovi and Erbitux also performed well, with an OS of 8.4 months. Kopetz tweeted that the response rates in second-line patients was 34% for the triplet, 22% for the ...

New research reinforcing the role of ERBITUX ® (cetuximab) in colorectal cancer (Abstracts 3513, LBA3500) Investigator-sponsored research continues to reinforce ERBITUX as the backbone of ...

MoA Clear Passage 2025 Fund earns a High Process Pillar rating. The primary contributor to the rating is its parent firm's impressive long-term risk-adjusted performance, as shown by the firm's ...

While the UHC Law was enacted in 2019, progress on this specific provision had stalled. “This MOA is more than just a formal document. It’s a symbol of shared vision, trust and commitment.

Now in recurrent metastatic head and neck cancer for specifically, even with a combination of chemotherapy and the EGFR inhibitor cetuximab or also known as Erbitux, the median overall survival is ...

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Pfizer Inc. (NYSE: PFE) today announced longer-term follow-up results from an open-label extension of the Phase 3 ...